Immutep Ltd (STU:YP1B)
€ 0.174 0.012 (7.41%) Market Cap: 260.89 Mil Enterprise Value: 149.39 Mil PE Ratio: 9,999.00 PB Ratio: 2.23 GF Score: 39/100

Immutep Ltd at NWR Communications Virtual Health Conference Transcript

May 04, 2020 / 04:50AM GMT
Release Date Price: €0.073787 (-26.47%)
Operator

No not seeing the NWR National Health Conference. Welcome back on the line. We have not waited all the way in Germany and Marc Voigt is from Immutep. Immutep is a globally active biotech companies that have a lead on the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.

Immunotherapy is dedicated to leveraging its technology and expertise to bring innovative treatment options to market to patients. It's maximized value to shareholders. Marc Voigt joins us from building, I believe, and Marc was appointed as senior and executive director in July 2014. He has extensive experience in the corporate and biotech sectors.

He's previously worked as a personal assistant to a member of the Executive Board of Alliance Insurance Marc has also worked for German Investment Bank net highest IPR AG net IPR AG. I'm sorry, in the area of business development and gentlemen, security offerings in the early 2000. He was investment manager and a new thought care VC funds in the biotech sector. Here's holes different executive positions formalized in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot